DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Relative Bioavailability Study of Citalopram HBr 10 mg Tablets Under Fasting Conditions

Information source: Actavis Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Citalopram HBr eq. 10 mg tablets, single dose (Drug); CELEXATM 10 mg tablets, single dose (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Actavis Inc.

Official(s) and/or principal investigator(s):
James D. Carlson,, Pharm.D,, Principal Investigator, Affiliation: PRACS Institute, Ltd.


The purpose of this study is compare the relative bioavailability of 10 mg Citalopram Hydrobromide tablets by Purepac Pharmaceutical Co with that of 10 mg CELEXATM tablets distributed and marketed by Forest Pharmaceuticals, Inc. following a single oral dose (1 x 10 mg tablet) in healthy adult volunteers under fasting conditions

Clinical Details

Official title: A Relative Bioavailability of 10 mg Citalopram Hydrobromide Tablets Under Fasting Conditions

Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label

Primary outcome: Rate and Extend of Absorption

Detailed description: Study Type: Interventional Study Design: Randomized, single-dose, two-way crossover study under fasting conditions Official Title: A Relative Bioavailability of 10 mg Citalopram Hydrobromide Tablets Under Fasting Conditions Further study details as provided by Actavis Elizabeth LLC: Primary Outcome Measures: Rate and Extend of Absorption


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria: 1. Screening Demographics: All volunteers selected for this study will be healthy men or women 18 years of age or older at the time of dosing. The weight range will not

exceed ± 20% for height and body frame as per Desirable Weights for Adults - 1983

Metropolitan Height and Weight Table. 2. Screening Procedures: Each volunteer will complete the screening process within 28 days prior to Period I dosing. Consent documents for both the screening evaluation and HIV antibody determination will be reviewed, discussed, and signed by each potential participant before full implementation of screening procedures. Screening will include general observations, physical examination, demographics, medical and medication history, an electrocardiogram, sitting blood pressure and

heart rate, respiratory rate and temperature. - The physical examination will include,

but may not be limited to, an evaluation of the cardiovascular, gastrointestinal, respiratory and central nervous systems. The screening clinical laboratory procedures will include:

- HEMATOLOGY: hematocrit, hemoglobin, WBC count with differential; RBC count,

platelet count;

- CLINICAL CHEMISTRY: serum creatinine, BUN, glucose, AST(GOT), ALT(GPT), albumin,

total bilirubin, total protein, and alkaline phosphatase;

- HIV antibody and hepatitis B surface antigen screens;

- URINALYSIS: by dipstick, microscopic examination if dipstick positive; and

- URINE DRUG SCREEN: ethyl alcohol, amphetamines, barbiturates, benzodiazepines,

cannabinoids, cocaine metabolites, opiates and phencyclidine.

- SERUM PREGNANCY SCREEN (female volunteers only)

3. If female and:

- of childbearing potential, is practicing an acceptable barrier method of birth

control for the duration of the study as judged by the investigator(s), such as condoms, sponge, foams, jellies, diaphragm; intrauterine device (IUD), or abstinence; or

- is postmenopausal for at least I year; or

- is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or

hysterectomy). Exclusion Criteria: 1. Volunteers with a recent history of drug or alcohol addiction or abuse. 2. Volunteers with the presence of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease (as determined by the medical investigator). 3. Volunteers whose clinical laboratory test values are outside the accepted reference range and when confirmed on re-examination are deemed to be clinically significant. 4. Volunteers demonstrating a positive hepatitis B surface antigen screen or a reactive HIV antibody screen. 5. Volunteers demonstrating a positive drug abuse screen when screened for this study. 6. Female volunteers demonstrating a positive pregnancy screen. 7. Female volunteers who are currently breastfeeding. 8. Volunteers with a history of allergic response(s) to citalopram or related drugs. 9. Volunteers with a history of clinically significant allergies including drug allergies. 10. Volunteers with a clinically significant illness during the 4 weeks prior to Period I dosing (as determined by the medical investigator). 11. Volunteers who currently use tobacco products. 12. Volunteers who have taken any drug known to induce or inhibit hepatic• drug metabolism in the 28 days prior to Period I dosing. 13. Volunteers who report donating greater than 150 mL of blood within 30 days prior to Period I dosing. All subjects will be advised not to donate blood for four weeks after completing the study. 14. Volunteers who have donated plasma (e. g. plasmapheresis) within 14 days prior to Period I dosing. All subjects will be advised not to donate plasma for four weeks after completing the study. 15. Volunteers who report receiving any investigational drug within 30 days prior to Period I dosing. 16. Volunteers who report taking any systemic prescription medication in the 14 days prior to Period I dosing.

Locations and Contacts

PRACS Institute, Ltd., Fargo, North Dakota 58102, United States
Additional Information


Starting date: July 2003
Last updated: August 13, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017